Cargando…

Oxygen-Ozone Therapy for Reducing Pro-Inflammatory Cytokines Serum Levels in Musculoskeletal and Temporomandibular Disorders: A Comprehensive Review

To date, the application of oxygen-ozone (O(2)O(3)) therapy has significantly increased in the common clinical practice in several pathological conditions. However, beyond the favorable clinical effects, the biochemical effects of O(2)O(3) are still far from being understood. This comprehensive revi...

Descripción completa

Detalles Bibliográficos
Autores principales: de Sire, Alessandro, Marotta, Nicola, Ferrillo, Martina, Agostini, Francesco, Sconza, Cristiano, Lippi, Lorenzo, Respizzi, Stefano, Giudice, Amerigo, Invernizzi, Marco, Ammendolia, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910188/
https://www.ncbi.nlm.nih.gov/pubmed/35269681
http://dx.doi.org/10.3390/ijms23052528
Descripción
Sumario:To date, the application of oxygen-ozone (O(2)O(3)) therapy has significantly increased in the common clinical practice in several pathological conditions. However, beyond the favorable clinical effects, the biochemical effects of O(2)O(3) are still far from being understood. This comprehensive review aimed at investigating the state of the art about the effects of O(2)O(3) therapy on pro-inflammatory cytokines serum levels as a modulator of oxidative stress in patients with musculoskeletal and temporomandibular disorders (TMD). The efficacy of O(2)O(3) therapy could be related to the moderate oxidative stress modulation produced by the interaction of ozone with biological components. More in detail, O(2)O(3) therapy is widely used as an adjuvant therapeutic option in several pathological conditions characterized by chronic inflammatory processes and immune overactivation. In this context, most musculoskeletal and temporomandibular disorders (TMD) share these two pathophysiological processes. Despite the paucity of in vivo studies, this comprehensive review suggests that O(2)O(3) therapy might reduce serum levels of interleukin 6 in patients with TMD, low back pain, knee osteoarthritis and rheumatic diseases with a concrete and measurable interaction with the inflammatory pathway. However, to date, further studies are needed to clarify the effects of this promising therapy on inflammatory mediators and their clinical implications.